The United States-based National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for CML suggest that NGS with a myeloid mutation panel should be considered for patients who present at an advanced disease stage or have disease progression to the advanced phases with no identifiable BCR::ABL1 kinase domain mutation. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.